Age and ageing · 2026
Pre-surgery statin use and outcomes in operated chronic subdural haematomas: a nationwide cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Posti Jussi P, Tornio Aleksi, Ruuskanen Jori O, Raj Rahul, Luoto Teemu, Tommiska Pihla, Kytö Ville
Аннотация
BACKGROUND: Chronic subdural haematoma (cSDH) is common in older adults, and medication exposures may influence postoperative outcomes. We assessed whether pre-surgery statin use is associated with short- and long-term outcomes.
METHODS: We conducted a nationwide registry study of adults undergoing surgical evacuation of traumatic or non-traumatic cSDH (6/2004-12/2018) in Finnish university hospitals. Pre-surgery statin use was defined from national prescription records using a pill-counting approach. The primary outcome was 30-day all-cause mortality. Secondary outcomes were 30-day reoperation and length of hospital stay. Tertiary outcomes were 1-year mortality and reoperation. Mortality was analysed using Cox regression; reoperation with Fine-Gray models accounting for competing risk of death.
RESULTS: The cohort included 9001 patients, of whom 2450 (27.2%) used statins. Thirty-day mortality was 3.3% in statin users and 4.5% in non-users, with lower adjusted mortality among statin users (HR 0.57; 95% CI 0.44-0.73). Reoperation within 30 days (n = 897) was similar between groups (sub-distribution HR 1.08; 95% CI 0.97-1.21). Hospital stay was shorter in statin users (22.1 ± 62.7 vs 26.3 ± 77.5 days; adjusted P = .002). At 1 year, mortality remained lower in statin users (13.3% vs 15.4%; HR 0.66; 95% CI 0.58-0.75), with no difference in reoperation (sub-distribution HR 1.09; 95% CI 0.96-1.22).
CONCLUSION: In this nationwide cohort of surgically treated cSDH patients, pre-surgery statin use was associated with lower short- and long-term mortality and shorter hospital stay, while reoperation rates were similar between statin users and non-users.
METHODS: We conducted a nationwide registry study of adults undergoing surgical evacuation of traumatic or non-traumatic cSDH (6/2004-12/2018) in Finnish university hospitals. Pre-surgery statin use was defined from national prescription records using a pill-counting approach. The primary outcome was 30-day all-cause mortality. Secondary outcomes were 30-day reoperation and length of hospital stay. Tertiary outcomes were 1-year mortality and reoperation. Mortality was analysed using Cox regression; reoperation with Fine-Gray models accounting for competing risk of death.
RESULTS: The cohort included 9001 patients, of whom 2450 (27.2%) used statins. Thirty-day mortality was 3.3% in statin users and 4.5% in non-users, with lower adjusted mortality among statin users (HR 0.57; 95% CI 0.44-0.73). Reoperation within 30 days (n = 897) was similar between groups (sub-distribution HR 1.08; 95% CI 0.97-1.21). Hospital stay was shorter in statin users (22.1 ± 62.7 vs 26.3 ± 77.5 days; adjusted P = .002). At 1 year, mortality remained lower in statin users (13.3% vs 15.4%; HR 0.66; 95% CI 0.58-0.75), with no difference in reoperation (sub-distribution HR 1.09; 95% CI 0.96-1.22).
CONCLUSION: In this nationwide cohort of surgically treated cSDH patients, pre-surgery statin use was associated with lower short- and long-term mortality and shorter hospital stay, while reoperation rates were similar between statin users and non-users.